Research programme: peptide therapeutics - Zealand Pharma
Alternative Names: ZP-1-98; ZP-3022; ZP-DI-70; ZP2435Latest Information Update: 28 May 2020
Price :
$50 *
At a glance
- Originator Zealand Pharma
- Class Antihyperglycaemics; Obesity therapies; Peptides
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Gastrin modulators; Glucagon receptor agonists; Glucagon-like peptide-1 receptor antagonists; Neuropeptide Y inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 28 May 2020 No recent reports of development identified for preclinical development in Obesity in Denmark (SC)
- 28 May 2020 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Denmark (Parenteral)
- 04 Oct 2017 Zealand Pharma and Torrey Pines Institute for Molecular Studies enter into a multi-target research collaboration to identify novel peptide therapeutics